Cynata Therapeutics logo

CYP - Cynata Therapeutics Share Price

A$0.495 0.0  5.3%

Last Trade - 03/08/21

Micro Cap
Market Cap £36.4m
Enterprise Value £23.2m
Revenue £33.3k
Position in Universe 1050th / 1947
Unlock CYP Revenue
Relative Strength (%)
1m -9.40%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -56.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.15 0.094 0.14 0.19 0.066 5.00 37.0
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, CynataTherapeutics Ltd revenues decreased 8% to A$33K. Net lossincreased 90% to A$4.8M. Revenues reflect a decrease indemand for the Company's products and services due tounfavorable market conditions. Higher net loss reflectsOther income decrease from A$4.4M (income) to A$0K,Employee benefits Expense increase of 51% to A$810K(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CYP Revenue Unlock CYP Revenue

Net Income

CYP Net Income Unlock CYP Revenue

Normalised EPS

CYP Normalised EPS Unlock CYP Revenue

PE Ratio Range

CYP PE Ratio Range Unlock CYP Revenue

Dividend Yield Range

CYP Dividend Yield Range Unlock CYP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CYP EPS Forecasts Unlock CYP Revenue
Profile Summary

Cynata Therapeutics Limited is a stem cell and regenerative medicine company. The Company is engaged in the development and commercialization of a mesenchymal stem cell (MSC) technology for human therapeutic use, Cymerus. Its Cymerus technology facilitates manufacture of MSCs from a single donor and a single donation. The Company's Cymerus platform stem cell technology is based upon stem cells known as mesenchymoangioblasts (MCAs). The Company's technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product. The Cymerus platform provides a source of MSCs that is independent of donor limitations and provides an off-the-shelf stem cell platform for therapeutic product use. The Company's MSCs produced using Cymerus technology, can be used to treat unrelated patients, without any need to match the recipient to the donor.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated March 12, 2003
Public Since December 20, 2007
No. of Shareholders: 3,534
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Australian Stock Exchange - SEATS
Shares in Issue 138,564,299
Free Float (0.0%)
Eligible for
View larger map
Address L 3 62 Lygon Street Carlton, MELBOURNE, 3053, Australia
Web https://www.cynata.com/
Phone +61 3 98245254
Contact ()
Auditors Stantons International Audit and Consulting PTY Ltd
CYP Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CYP
Upcoming Events for CYP
Monday 23rd August, 2021 Estimate
Full Year 2021 Cynata Therapeutics Ltd Earnings Release
Wednesday 24th November, 2021 Estimate
Cynata Therapeutics Ltd Annual Shareholders Meeting
Frequently Asked Questions for Cynata Therapeutics
What is the Cynata Therapeutics share price?

As of 03/08/21, shares in Cynata Therapeutics are trading at A$0.495, giving the company a market capitalisation of £36.4m. This share price information is delayed by 15 minutes.

How has the Cynata Therapeutics share price performed this year?

Shares in Cynata Therapeutics are currently trading at A$0.495 and the price has moved by -21.19% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cynata Therapeutics price has moved by -38.44% over the past year.

What are the analyst and broker recommendations for Cynata Therapeutics?

Of the analysts with advisory recommendations for Cynata Therapeutics, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Cynata Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Cynata Therapeutics next release its financial results?

Cynata Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Cynata Therapeutics dividend yield?

Cynata Therapeutics does not currently pay a dividend.

Does Cynata Therapeutics pay a dividend?

Cynata Therapeutics does not currently pay a dividend.

When does Cynata Therapeutics next pay dividends?

Cynata Therapeutics does not currently pay a dividend.

How do I buy Cynata Therapeutics shares?

To buy shares in Cynata Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cynata Therapeutics?

Shares in Cynata Therapeutics are currently trading at A$0.495, giving the company a market capitalisation of £36.4m.

Where are Cynata Therapeutics shares listed? Where are Cynata Therapeutics shares listed?

Here are the trading details for Cynata Therapeutics:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: CYP
What kind of share is Cynata Therapeutics?

Based on an overall assessment of its quality, value and momentum, Cynata Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Cynata Therapeutics share price forecast 2021?

Shares in Cynata Therapeutics are currently priced at A$0.495. At that level they are trading at 0.403% discount to the analyst consensus target price of 0.00.

Analysts covering Cynata Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -0.04 for the next financial year.

How can I tell whether the Cynata Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cynata Therapeutics. Over the past six months, the relative strength of its shares against the market has been -31.9%. At the current price of A$0.495, shares in Cynata Therapeutics are trading at -24.31% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cynata Therapeutics PE Ratio?

We were not able to find PE ratio data for Cynata Therapeutics.

Who are the key directors of Cynata Therapeutics?

Cynata Therapeutics's management team is headed by:

Ross Macdonald - CEO
Stewart Washer - NED
Paul Wotton - NED
Geoffrey Brooke - CHM
Suzanne Lipe - VPR
Kilian Kelly - COO
Darryl Maher - NID
Who are the major shareholders of Cynata Therapeutics?

Here are the top five shareholders of Cynata Therapeutics based on the size of their shareholding:

Phillip Asset Management Limited Investment Advisor
Percentage owned: 9.97% (14.3m shares)
Fidelity Funds - Pacific Fund Mutual Fund
Percentage owned: 8.21% (11.8m shares)
Fidelity International Investment Advisor
Percentage owned: 8.21% (11.8m shares)
FIL Investment Management (Hong Kong) Limited Investment Advisor
Percentage owned: 7.62% (10.9m shares)
FUJIFILM Corporation Corporation
Percentage owned: 5.65% (8.09m shares)
Similar to CYP
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.